Introduction: Biologic therapies are licensed for both psoriasis (PsO) and psoriatic arthritis (PsA) with some electronic medical record data suggest that IL (Interleukin)-23 blockers might be more protective in PsA prevention than TNF blockers; however, the findings have been inconsistent. Higher ...
Many of us who are diagnosed with psoriasis and psoriatic arthritis have been prescribed both of these type of medications. Knowing the difference between the two medications is important. When deciding which path you want to take treating our disease, knowledge can help avoid critical mistakes that...
& Bao, Y. Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: a matching-adjusted indirect comparison. Arthritis Rheumatol. Abstr. 67 (Suppl. 10), 2868 (2015). Google Scholar Hsu, L., Snodgrass, B. T. & Armstrong, A. W. Antidrug antibodies in psoriasis: a...
& Bao, Y. Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: a matching-adjusted indirect comparison. Arthritis Rheumatol. Abstr. 67 (Suppl. 10), 2868 (2015). Google Scholar Hsu, L., Snodgrass, B. T. & Armstrong, A. W. Antidrug antibodies in psoriasis: a...
The impact of early versus late transition on disease activity was assessed using multivariate linear regression, with the 5-year adjusted mean swollen joint count (SJC) as the outcome. The influence on damage was evaluated using Cox regression, with time to radiographic progression as the outcome...
Psoriasis can be aggravated into Psoriatic Arthritis. Moreover, psoriasis sufferers can develop cancer of white blood cells, a Heart Attack (due to inflammation found in Psoriasis), that can seriously endanger your life. A recent U.K study has clearly shown that psoriasis sufferers tend to ...
“In an ideal world, we’d have a better handle on which treatments work best for guttate psoriasis versus, say, plaque psoriasis, but we don’t have that yet,” he says. “We tend to tailor the treatment to the person rather than the condition.” These are some of the options you...
At 16 weeks in the two ESTEEM trials, apremilast reduced the severity and extent of moderate to severe plaque psoriasis, including nail, scalp and palmoplantar manifestations, versus placebo in adults, with these benefits generally being sustained over 52 weeks of treatment. Similarly, in three ...
Heydendael VMR, Spuls PI, Opmeer BC, et al. (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Eng J Med 349: 658–665 CASGoogle Scholar Higgins EM, du Vivier AW (1994a) Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 30...
Pullmann H, Enderer K, Steigleder GK (1981) Cytokinetic effects of anthralin on psoriatic keratinocytes. Br J Dermatol 105:55–56 ArticlePubMedGoogle Scholar Raab WG (1976) Dithranol (anthralin) versus triacetoxy-anthracene. Br J Dermatol 95:193–196 ...